Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES et al
Case Number:
1:14-cv-01685
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
October 14, 2015
340B Orphan Drug Discounts Dialed Back
The Affordable Care Act fully exempts orphan drugs from mandatory discounts under the 340B program for certain health care providers, a D.C. federal judge said Wednesday in an important victory for trade group Pharmaceutical Research and Manufacturers of America.
-
July 06, 2015
Life Sciences Cases To Watch In The 2nd Half Of 2015
The pharmaceutical industry is poised for important court developments involving off-label marketing, biosimilars exclusivity, False Claims Act liability and the 340B drug-discount program. Here are four cases that attorneys will be tracking closely in the second half of 2015.
-
July 02, 2015
Health Cases To Watch In The 2nd Half Of 2015
The second half of 2015 is shaping up as a potential litigation blockbuster for health care providers, as major developments loom in cases involving the False Claims Act, the future of crucial Affordable Care Act funding and the 340B drug-discount program. Here are six cases that attorneys will be watching closely.
-
April 14, 2015
PhRMA Presses Case For Dumping 340B Orphan Drug Rule
Pharmaceutical Research and Manufacturers of America is once again pushing a D.C. federal court to nix a U.S. Department of Health and Human Services interpretative rule on discounts for orphan drugs under the 340B program, arguing that the rule has legally binding consequences that are ripe for judicial review.
-
March 23, 2015
HHS Fights Court Review In 340B Orphan Drug Row
The U.S. Department of Health and Human Services is fighting to block court review of its policy on discounts for orphan drugs in the 340B program, telling a D.C. federal judge that judicial scrutiny is inappropriate because the policy isn't binding.
-
February 26, 2015
PhRMA Seeks Quick Win In 340B Orphan Drug Suit
Pharmaceutical Research and Manufacturers of America on Wednesday urged a D.C. federal judge to ax a regulation involving discounts for orphan drugs, setting the stage for an important decision on the 340B program's future.
-
January 28, 2015
HHS Asks DC Court To Nix PhRMA's 340B Orphan Drug Suit
The U.S. Department of Health and Human Services asked a D.C. federal court Tuesday to toss Pharmaceutical Research and Manufacturers of America's complaint challenging a department rule on discounting so-called orphan drugs in the 340B program, saying the interpretive rule wasn't subject to the court's review.
-
October 09, 2014
PhRMA Launches New Suit Over 340B Orphan Drug Rule
Reviving a high-stakes fight, Pharmaceutical Research and Manufacturers of America on Thursday sued the U.S. Department of Health and Human Services in D.C. federal court to prevent regulators from disciplining drugmakers that sometimes withhold discounts on so-called orphan drugs in the 340B program.